Genomic & Epigenomic Profiling Market Size is valued at US$ 5.5 Bn in 2024 and is predicted to reach US$ 23.2 Bn by the year 2034 at an 15.8% CAGR during the forecast period for 2025-2034.
Genomic and epigenomic profiling are advanced analytical approaches used to understand the genetic blueprint of an organism and the regulatory mechanisms that control gene expression. Genomic profiling identifies variations in DNA sequences, such as mutations, copy-number changes, and structural alterations that influence disease susceptibility and therapeutic response.
Epigenomic profiling, on the other hand, examines reversible chemical modifications such as DNA methylation, histone modifications, and chromatin accessibility that determine how genes are turned on or off without altering the underlying DNA. Together, these profiling techniques provide comprehensive insights into disease mechanisms, enabling precision medicine, biomarker discovery, and targeted therapeutic development. The market's expansion is primarily attributable to advancements in genomic and epigenomic sequencing technology, rising rates of cancer and uncommon diseases, and a growing emphasis on individualized healthcare solutions worldwide.
In addition, increased investments by pharmaceutical and biotech companies in the development of targeted medicines will accelerate the expansion of the genomic and epigenomic profiling market over the forecast period. Increased government financing, expanded research activities, and increased clinical trial inclusion for genetic profiling are all contributing to market growth.
The surge in precision medicine, driven by genetic insights, as well as the development of regulatory approvals for companion diagnostics, is driving global expansion of the genomic and epigenomic profiling market. Furthermore, improvements in NGS have become a cornerstone in the global genomic and epigenomic profiling market. These NGS technologies offer a paradigm leap in genomic analysis, providing unsurpassed speed, scalability, and cost-efficiency when compared to traditional sequencing approaches.
Some of the Key Players in Genomic & Epigenomic Profiling Market:
· Illumina
· Thermo Fisher Scientific
· Agilent Technologies
· Bio-Rad Laboratories
· Roche
· Qiagen
· PerkinElmer
· Pacific Biosciences
· BGI Genomics
· New England Biolabs
· Merck KGaA
· Diagenode
· Promega Corporation
· 10x Genomics
· Oxford Nanopore Technologies
· QIAGEN
· Zymo Research
· Fulgent Genetics
· GENEWIZ
· Eurofins Scientific
· Invitae
· Myriad Genetics
· Adaptive Biotechnologies
· Guardant Health
· Invivoscribe
· Others
The genomic & epigenomic profiling market is segmented by type, application, technology, and end-use. By type, the market is segmented into genomic profiling and epigenomic profiling. By application, the market is segmented into clinical diagnostics, agriculture & animal research, and drug discovery & development. By technology, the market is segmented into NGS, PCR-based, and microarray. By end-use, the market is segmented into hospitals, pharmaceuticals, and research institutes.
The genomic profiling segment held the largest share in the market. The expanding demand for gene therapy, customized medicine, and drug development, the rising incidence of cancer, and the notable rise in consumer genomics demand in recent years are all factors contributing to the growth of the genomics profiling category in the genomic and epigenomic profiling market. Additionally, it is anticipated that the expansion of this segment would benefit from increased joint ventures and collaborations among market participants.
In 2024, the global genomic and epigenomic profiling market was dominated by the hospitals segment. This is because the application of genomic and epigenomic profiling technologies for precision medicine, especially in oncology, is heavily influenced by hospitals. They have the infrastructure, knowledge, and patient data needed to facilitate the smooth integration of genomic and epigenomic profiling into standard clinical procedures. Additionally, the segemnt’s dominance is partly due to patients' and healthcare professionals' growing knowledge of the advantages of personalized medicine.
In 2024, the North American region dominated the genomic and epigenomic profiling market. The existence of cutting-edge healthcare infrastructure, high adoption of advanced diagnostic tools, and substantial investments in genomic and epigenomic research and development provide the foundation for this leadership position. Leading genomic and epigenomic technology suppliers, academic institutions, and reference labs are concentrated in the United States, in particular, which propels market expansion and innovation. Additionally, the region's dominance in the worldwide genomic and epigenomic profiling market is further enhanced by favorable reimbursement policies, supportive regulatory frameworks, and a strong emphasis on precision medicine.
During the projection period, the Asia Pacific region is expected to grow at the fastest rate in the genomic and epigenomic profiling market, driven by rising healthcare costs, greater awareness of chronic illnesses, and increased investments in healthcare infrastructure. Furthermore, the growing healthcare industry and the increasing emphasis on precision medicine have made countries such as China, Japan, and India significant contributors to the genomic and epigenomic profiling market. The market expansion in this area is also anticipated to be fueled by the rising incidence of chronic illnesses and the growing curiosity about their origins.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 5.5 Bn |
| Revenue Forecast In 2034 | USD 23.2 Bn |
| Growth Rate CAGR | CAGR of 15.8% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Type, By Application, By Technology, By End-use, and By Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; Germany; The UK; France; Italy; Spain; Rest of Europe; China; Japan; India; South Korea; Southeast Asia; Rest of Asia Pacific; Brazil; Argentina; Mexico; Rest of Latin America; GCC Countries; South Africa; Rest of the Middle East and Africa |
| Competitive Landscape | Illumina, Thermo Fisher Scientific, Agilent Technologies, Bio-Rad Laboratories, Roche, Qiagen, PerkinElmer, Pacific Biosciences, BGI Genomics, New England Biolabs, Merck KGaA, Diagenode, Promega Corporation, 10x Genomics, Oxford Nanopore Technologies, QIAGEN, Zymo Research, Fulgent Genetics, GENEWIZ, Eurofins Scientific, Invitae, Myriad Genetics, Adaptive Biotechnologies, Guardant Health, and Invivoscribe |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Genomic & Epigenomic Profiling Market by Type
· Genomic Profiling
· Epigenomic Profiling
Genomic & Epigenomic Profiling Market by Application
· Clinical Diagnostics
· Agriculture & Animal Research
· Drug Discovery & Development
Genomic & Epigenomic Profiling Market by Technology
· NGS
· PCR-based
· Microarray
Genomic & Epigenomic Profiling Market by End-use
· Hospitals
· Pharmaceuticals
· Research Institutes
Genomic & Epigenomic Profiling Market by Region
North America-
· The US
· Canada
Europe-
· Germany
· The UK
· France
· Italy
· Spain
· Rest of Europe
Asia-Pacific-
· China
· Japan
· India
· South Korea
· Southeast Asia
· Rest of Asia Pacific
Latin America-
· Brazil
· Argentina
· Mexico
· Rest of Latin America
Middle East & Africa-
· GCC Countries
· South Africa
· Rest of the Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Genomic & Epigenomic Profiling Market Snapshot
Chapter 4. Global Genomic & Epigenomic Profiling Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global Genomic & Epigenomic Profiling Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on Genomic & Epigenomic Profiling Market Industry Trends
Chapter 5. Genomic & Epigenomic Profiling Market Segmentation 1: By Type, Estimates & Trend Analysis
5.1. Market Share by Type, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Type:
5.2.1. Genomic Profiling
5.2.2. Epigenomic Profiling
Chapter 6. Genomic & Epigenomic Profiling Market Segmentation 2: By Application, Estimates &
Trend Analysis
6.1. Market Share by Application, 2024 & 2034
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following
Application:
6.2.1. Clinical Diagnostics
6.2.2. Drug Discovery & Development
6.2.3. Agriculture & Animal Research
Chapter 7. Genomic & Epigenomic Profiling Market Segmentation 3: By End-use, Estimates & Trend Analysis
7.1. Market Share by End-use, 2024 & 2034
7.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following End-use:
7.2.1. Pharmaceuticals
7.2.2. Research Institutes
7.2.3. Hospitals
Chapter 8. Genomic & Epigenomic Profiling Market Segmentation 4: By Technology, Estimates & Trend Analysis
8.1. Market Share by Technology, 2024 & 2034
8.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Technology:
8.2.1. NGS
8.2.2. Microarray
8.2.3. PCR-based
Chapter 9. Genomic & Epigenomic Profiling Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global Genomic & Epigenomic Profiling Market, Regional Snapshot 2024 & 2034
9.2. North America
9.2.1. North America Genomic & Epigenomic Profiling Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Genomic & Epigenomic Profiling Market Revenue (US$ Mn) Estimates and Forecasts by Type, 2021-2034
9.2.3. North America Genomic & Epigenomic Profiling Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
9.2.4. North America Genomic & Epigenomic Profiling Market Revenue (US$ Mn) Estimates and Forecasts by End-use, 2021-2034
9.2.5. North America Genomic & Epigenomic Profiling Market Revenue (US$ Mn) Estimates and Forecasts by Technology, 2021-2034
9.3. Europe
9.3.1. Europe Genomic & Epigenomic Profiling Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe Genomic & Epigenomic Profiling Market Revenue (US$ Mn) Estimates and Forecasts by Type, 2021-2034
9.3.3. Europe Genomic & Epigenomic Profiling Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
9.3.4. Europe Genomic & Epigenomic Profiling Market Revenue (US$ Mn) Estimates and Forecasts by End-use, 2021-2034
9.3.5. Europe Genomic & Epigenomic Profiling Market Revenue (US$ Mn) Estimates and Forecasts by Technology, 2021-2034
9.4. Asia Pacific
9.4.1. Asia Pacific Genomic & Epigenomic Profiling Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific Genomic & Epigenomic Profiling Market Revenue (US$ Mn) Estimates and Forecasts by Type, 2021-2034
9.4.3. Asia Pacific Genomic & Epigenomic Profiling Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
9.4.4. Asia Pacific Genomic & Epigenomic Profiling Market Revenue (US$ Mn) Estimates and Forecasts by End-use, 2021-2034
9.4.5. Asia Pacific Genomic & Epigenomic Profiling Market Revenue (US$ Mn) Estimates and Forecasts by Technology, 2021-2034
9.5. Latin America
9.5.1. Latin America Genomic & Epigenomic Profiling Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America Genomic & Epigenomic Profiling Market Revenue (US$ Mn) Estimates and Forecasts by Type, 2021-2034
9.5.3. Latin America Genomic & Epigenomic Profiling Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
9.5.4. Latin America Genomic & Epigenomic Profiling Market Revenue (US$ Mn) Estimates and Forecasts by End-use, 2021-2034
9.5.5. Latin America Genomic & Epigenomic Profiling Market Revenue (US$ Mn) Estimates and Forecasts by Technology, 2021-2034
9.6. Middle East & Africa
9.6.1. Middle East & Africa Genomic & Epigenomic Profiling Market Revenue (US$ Mn) Estimates and Forecasts by country, 2021-2034
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa Genomic & Epigenomic Profiling Market Revenue (US$ Mn) Estimates and Forecasts by Type, 2021-2034
9.6.3. Middle East & Africa Genomic & Epigenomic Profiling Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
9.6.4. Middle East & Africa Genomic & Epigenomic Profiling Market Revenue (US$ Mn) Estimates and Forecasts by End-use, 2021-2034
9.6.5. Middle East & Africa Genomic & Epigenomic Profiling Market Revenue (US$ Mn) Estimates and Forecasts by Technology, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Illumina (USA)
10.2.1.1. Business Overview
10.2.1.2. Key Product/Service
10.2.1.3. Financial Performance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. Thermo Fisher Scientific (USA)
10.2.3. Agilent Technologies (USA)
10.2.4. Bio-Rad Laboratories (USA)
10.2.5. Roche (Switzerland)
10.2.6. Qiagen (Germany)
10.2.7. PerkinElmer (USA)
10.2.8. Pacific Biosciences (USA)
10.2.9. BGI Genomics (China)
10.2.10. New England Biolabs (USA)
10.2.11. Merck KGaA (Germany)
10.2.12. Diagenode (Belgium)
10.2.13. Promega Corporation (USA)
10.2.14. 10x Genomics (USA)
10.2.15. Oxford Nanopore Technologies (UK)
10.2.16. QIAGEN (Germany)
10.2.17. Zymo Research (USA)
10.2.18. Fulgent Genetics (USA)
10.2.19. GENEWIZ (USA)
10.2.20. Eurofins Scientific (Luxembourg)